文献速递细菌感染、耐药与抗菌药物医院感染防控

多黏菌素相关急性肾损伤的病理生理、危险因素与临床管理

Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本文综述多黏菌素相关急性肾损伤(PA-AKI)的病理生理、危险因素与临床管理。减少合并肾毒性药物暴露、规范监测血肌酐、尿量和多黏菌素浓度有助于降低PA-AKI风险与进展;部分生物标志物有早期预测前景但尚待广泛临床验证。

要点

  • 减少合并肾毒性药物暴露是降低PA-AKI风险的关键措施。
  • 规范监测血肌酐、尿量和多黏菌素浓度有助于防控PA-AKI。
  • 部分生物标志物可早期预测PA-AKI,但尚待广泛临床验证。

核心结论

  • 减少合并肾毒性药物暴露并规范监测血肌酐、尿量和多黏菌素浓度,对降低PA-AKI风险与进展起关键作用。
  • 部分生物标志物有早期预测PA-AKI的前景,但许多尚未经过广泛临床验证。

研究设计与样本

  • 本文为综述,分析PA-AKI的病理生理、危险因素与临床管理。

主要发现

  • 多黏菌素是革兰阴性菌感染的「最后防线」,常用于多重耐药病原体感染的危重患者。
  • PA-AKI仍是限制多黏菌素临床应用的主要因素。
  • 减少合并肾毒性药物暴露与规范监测血肌酐、尿量和多黏菌素浓度有助于降低PA-AKI风险与进展。
  • 部分生物标志物有早期预测PA-AKI的前景,但许多尚未经过广泛临床验证。

临床怎么用

  • 临床使用多黏菌素时应减少合并肾毒性药物暴露。
  • 应规范监测血肌酐、尿量和多黏菌素浓度以防控PA-AKI。

局限性

  • 许多生物标志物尚未经过广泛临床验证。
  • 需要将真实世界证据纳入多黏菌素使用临床实践指南。
  • 需进一步研究PA-AKI的遗传危险因素及开发肾毒性更低的新型多黏菌素类似物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polymyxins serve as a 'last-line' defence against Gram-negative bacterial infections and are frequently used in critically ill patients with multidrug-resistant pathogens. However, polymyxin-associated acute kidney injury (PA-AKI) remains a major factor limiting their clinical application. This review examines the pathophysiology, risk factors and clinical management of PA-AKI, providing updated perspectives on its prevention and treatment. Reducing exposure to concomitant nephrotoxic agents, together with timely and standardized monitoring of serum creatinine, urine volume and polymyxin concentrations, plays a key role in mitigating the risk and progression of PA-AKI. Although several biomarkers show promise for the early prediction of PA-AKI and may enable earlier intervention, many have not yet undergone extensive clinical validation. There is a clear need to incorporate real-world evidence into clinical practice guidelines for polymyxin use. Further research should focus on identifying genetic risk factors for PA-AKI and developing novel polymyxin analogues with reduced nephrotoxicity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhao S, Mu G, Liu X, et al. Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury. J Antimicrob Chemother. 2026. PMID: 41964474. doi:10.1093/jac/dkag132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。